AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

The company announced significant advancements in breast cancer treatment, with its drug Enhertu receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

NEW YORK – AstraZeneca on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the HER2-targeted antibody-drug conjugate Enhertu (trastuzumab ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Check out the new awareness resources and share information about the front-of-package nutrition symbol. The front-of-package nutrition symbol is mandatory for prepackaged foods that meet or exceed ...

Enhertu's success can be attributed to its unique mechanism ... Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable ...